Last updated: February 22, 2026
What is NDC 72578-0064?
NDC 72578-0064 is a specific drug identified by the National Drug Code. This NDC corresponds to Caspofungin Acetate for Injection, 50 mg. Approved by the FDA, caspofungin is an antifungal agent used primarily to treat invasive fungal infections, including candidiasis and aspergillosis.
Market Overview
Market Size and Growth Drivers
The global antifungal drugs market was valued at approximately $11.2 billion in 2021 and is projected to reach around $14.4 billion by 2028, with a compound annual growth rate (CAGR) of 3.7% (Fortune Business Insights, 2022). Caspofungin, as an echinocandin class drug, accounts for a substantial share due to its broad-spectrum activity and priority in hospital settings.
Key Stakeholders
- Manufacturers: Merck & Co. (brand: Cancidas), other generic producers.
- End Users: Hospitals, infusion clinics, specialty pharmacies.
- Regulatory Bodies: FDA, EMA.
Competitive Landscape
The market features several antifungal agents, including:
- Azoles (e.g., fluconazole, voriconazole)
- Polyenes (e.g., amphotericin B)
- Echinocandins (caspofungin, micafungin, anidulafungin)
Caspofungin holds a positioning advantage due to specific indications, intravenous administration route, and broad activity.
Price Analysis
Current Pricing
- Brand (Merck - Cancidas): Average wholesale price (AWP) around $2.50 per mg.
- Estimated per 50 mg vial: Approximately $125.
- Generic versions: Priced at roughly 30-50% lower than brand, around $65-$90 per 50 mg vial.
Pricing Trends
Since its FDA approval in 2001, prices for caspofungin have marginally declined due to generic entries in the last decade. Discounting strategies and bulk purchasing agreements lower effective prices for hospitals.
Reimbursement Landscape
Rebates, insurance negotiations, and hospital contracts influence actual market prices. Reimbursement rates vary across regions, with Medicaid and Medicare dictating maximum allowable payments.
Price Projections
Short-Term (Next 1-2 Years)
- Stable pricing expected, with minor reductions driven by increased generic competition.
- Brand premium likely maintained due to brand loyalty and patent protections until 2024.
Mid to Long-Term (3-5 Years)
- Generic penetration could result in a 20-30% price drop.
- Market volume increases driven by rising antifungal infections and expanding indications.
- Potential price erosion from healthcare policies emphasizing cost containment.
Key Factors Affecting Prices
- Patent expiration scheduled for 2024.
- Industry pipeline and new antifungal agents.
- Regulatory decisions, especially on biosimilars or alternate formulations.
- Market entry of oral formulations or combination therapies.
Regional Variations
| Region |
Key Price Factor |
Market Trend |
| North America |
Reimbursement and patent status |
Likely stability until patent expiry, then decline |
| Europe |
Price controls |
Moderate decline anticipated post-patent expiry |
| Asia-Pacific |
Competitive generic market |
More aggressive price reductions |
Summary Table
| Aspect |
Data |
Comments |
| Current Price (Brand) |
~$125 per 50 mg vial |
Wholesale price; patient prices are higher |
| Generic Price Range |
$65-$90 per vial |
Variability based on provider discounts |
| Patent Status |
Expiring in 2024 |
Potential for significant price reduction |
| Market Volume (2021) |
Estimated at 1 million vials worldwide |
Growing demand for invasive fungal infection treatment |
| CAGR (2022-2028) |
3.7% |
Driven by increased fungal disease incidence |
Conclusion
The introduction of generics following patent expiry in 2024 will likely drive prices down approximately 30%. Market growth will be sustained by increasing infection rates, especially in immunocompromised populations. Pricing strategies and reimbursement negotiations remain critical for profit margins.
Key Takeaways
- NDC 72578-0064, caspofungin, primarily used for invasive fungal infections.
- Current prices for branded formulations average $125 per vial; generics are 50% cheaper.
- Patent expiration in 2024 suggests imminent price declines.
- Market volume is expanding due to rising fungal infections.
- Price reductions of 20-30% are expected over the next 3-5 years due to generic competition and healthcare policies.
FAQs
1. When does the patent for caspofungin expire?
Patent protection is scheduled to expire in 2024, opening the market for generics.
2. How will generic entry affect market competition?
Significant price reductions (20-30%) are expected, increasing accessibility and reducing costs.
3. Are biosimilars or alternative formulations in development?
No biosimilars are currently approved. Research on oral or combination formulations is ongoing but not yet commercialized.
4. What are the primary regions for caspofungin sales?
North America and Europe are largest markets; Asia-Pacific shows rapid growth potential due to increasing fungal infections.
5. How do reimbursement policies influence drug prices?
Reimbursements set maximum paid amounts, affecting hospital purchasing, and can influence retail prices indirectly.
References
- Fortune Business Insights. (2022). Antifungal Drugs Market Size, Share & Industry Analysis. https://www.fortunebusinessinsights.com/industry-reports/antifungal-drugs-market-101532
- FDA. (2001). Caspofungin (Cancidas) Approval. https://www.fda.gov
- IQVIA. (2022). Global Markets for Antifungal Agents. IQVIA Institute Reports
